Loading…
Comèl-Netherton syndrome defined as primary immunodeficiency
Background Mutations in serine protease inhibitor Kazal-type 5 ( SPINK5 ), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comèl-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic d...
Saved in:
Published in: | Journal of allergy and clinical immunology 2009-09, Vol.124 (3), p.536-543 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33 |
---|---|
cites | cdi_FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33 |
container_end_page | 543 |
container_issue | 3 |
container_start_page | 536 |
container_title | Journal of allergy and clinical immunology |
container_volume | 124 |
creator | Renner, Ellen D., MD Hartl, Dominik, MD Rylaarsdam, Stacey, AAS Young, Marguerite L., BS Monaco-Shawver, Linda, BA Kleiner, Gary, MD Markert, M. Louise, MD Stiehm, E. Richard, MD Belohradsky, Bernd H., MD Upton, Melissa P., MD Torgerson, Troy R., MD, PhD Orange, Jordan S., MD, PhD Ochs, Hans D., MD |
description | Background Mutations in serine protease inhibitor Kazal-type 5 ( SPINK5 ), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comèl-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic diathesis. Despite increased frequency of infections, the immunocompetence of patients with Comèl-Netherton syndrome has not been extensively investigated. Objective To define Comèl-Netherton syndrome as a primary immunodeficiency disorder and to explore the benefit of intravenous immunoglobulin replacement therapy. Methods We enrolled 9 patients with Comèl-Netherton syndrome, sequenced SPINK5, and analyzed LEKTI expression by immunohistochemistry. Immune function was assessed by measuring cognate immunity, serum cytokine levels, and natural killer cell cytotoxicity. Results All patients presented with recurrent skin infections caused predominantly by Staphylococcus aureus. All but 1 reported recurrent respiratory tract infections; 78% had sepsis and/or pneumonia; 67% had recurrent gastrointestinal disease and failure to thrive. Mutations in SPINK5 —including 6 novel mutations—were identified in 8 patients. LEKTI expression was decreased or absent in all patients. Immunologic evaluation revealed reduced memory B cells and defective responses to vaccination with Pneumovax and bacteriophage phiX174, characterized by impaired antibody amplification and class-switching. Immune dysregulation was suggested by a skewed T h 1 phenotype and elevated proinflammatory cytokine levels, whereas serum concentrations of the chemokine (C-C motif) ligand 5 and natural killer cell cytotoxicity were decreased. Treatment with intravenous immunoglobulin resulted in remarkable clinical improvement and temporarily increased natural killer cell cytotoxicity. Conclusion These data provide new insights into the immunopathology of Comèl-Netherton syndrome and demonstrate that this multisystem disorder, characterized by lack of LEKTI expression in epithelial cells, is complicated by cognate and innate immunodeficiency that responds favorably to intravenous immunoglobulin therapy. |
doi_str_mv | 10.1016/j.jaci.2009.06.009 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3685174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674909008781</els_id><sourcerecordid>21098632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33</originalsourceid><addsrcrecordid>eNqFks9u1DAQxi0EosvCC3BAkZC4JfhPYjsSVKpWlCJVcADOlmPPUofELnZSad-I9-DFcLqrlvZQTiN7fvNpZr5B6CXBFcGEv-2rXhtXUYzbCvMqh0doRXArSi5p8xit8g8puajbI_QspR7nN5PtU3REWi4ZY3yF3m_C-Of3UH6G6QLiFHyRdt7GMEJhYes82EKn4jK6Ucdd4cZx9mFJGAfe7J6jJ1s9JHhxiGv0_fTDt81Zef7l46fNyXlpOGNTSbcGWKMbTqg1ouFcGCNYa4XNfRBhqcQgOgy8bruO2aZjlNqu06buOMEdY2t0vNe9nLsRrAE_RT2oQ1sqaKfuZry7UD_ClWJcNkTUWeDNQSCGXzOkSY0uGRgG7SHMSXHBmWDN_0Ga9ys5oxl8fQ_swxx93oIiDa4laWRNMkX3lIkhpQjbm54JVouJqleLiWoxUWGuFovW6NW_096WHFzLwLs9AHnnVw6iStd-gHURzKRscA_rH98rN4PzzujhJ-wg3c6hElVYfV3OaLki3GIshSTsLymhw6I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504815841</pqid></control><display><type>article</type><title>Comèl-Netherton syndrome defined as primary immunodeficiency</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Renner, Ellen D., MD ; Hartl, Dominik, MD ; Rylaarsdam, Stacey, AAS ; Young, Marguerite L., BS ; Monaco-Shawver, Linda, BA ; Kleiner, Gary, MD ; Markert, M. Louise, MD ; Stiehm, E. Richard, MD ; Belohradsky, Bernd H., MD ; Upton, Melissa P., MD ; Torgerson, Troy R., MD, PhD ; Orange, Jordan S., MD, PhD ; Ochs, Hans D., MD</creator><creatorcontrib>Renner, Ellen D., MD ; Hartl, Dominik, MD ; Rylaarsdam, Stacey, AAS ; Young, Marguerite L., BS ; Monaco-Shawver, Linda, BA ; Kleiner, Gary, MD ; Markert, M. Louise, MD ; Stiehm, E. Richard, MD ; Belohradsky, Bernd H., MD ; Upton, Melissa P., MD ; Torgerson, Troy R., MD, PhD ; Orange, Jordan S., MD, PhD ; Ochs, Hans D., MD</creatorcontrib><description>Background Mutations in serine protease inhibitor Kazal-type 5 ( SPINK5 ), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comèl-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic diathesis. Despite increased frequency of infections, the immunocompetence of patients with Comèl-Netherton syndrome has not been extensively investigated. Objective To define Comèl-Netherton syndrome as a primary immunodeficiency disorder and to explore the benefit of intravenous immunoglobulin replacement therapy. Methods We enrolled 9 patients with Comèl-Netherton syndrome, sequenced SPINK5, and analyzed LEKTI expression by immunohistochemistry. Immune function was assessed by measuring cognate immunity, serum cytokine levels, and natural killer cell cytotoxicity. Results All patients presented with recurrent skin infections caused predominantly by Staphylococcus aureus. All but 1 reported recurrent respiratory tract infections; 78% had sepsis and/or pneumonia; 67% had recurrent gastrointestinal disease and failure to thrive. Mutations in SPINK5 —including 6 novel mutations—were identified in 8 patients. LEKTI expression was decreased or absent in all patients. Immunologic evaluation revealed reduced memory B cells and defective responses to vaccination with Pneumovax and bacteriophage phiX174, characterized by impaired antibody amplification and class-switching. Immune dysregulation was suggested by a skewed T h 1 phenotype and elevated proinflammatory cytokine levels, whereas serum concentrations of the chemokine (C-C motif) ligand 5 and natural killer cell cytotoxicity were decreased. Treatment with intravenous immunoglobulin resulted in remarkable clinical improvement and temporarily increased natural killer cell cytotoxicity. Conclusion These data provide new insights into the immunopathology of Comèl-Netherton syndrome and demonstrate that this multisystem disorder, characterized by lack of LEKTI expression in epithelial cells, is complicated by cognate and innate immunodeficiency that responds favorably to intravenous immunoglobulin therapy.</description><identifier>ISSN: 0091-6749</identifier><identifier>ISSN: 1097-6825</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2009.06.009</identifier><identifier>PMID: 19683336</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Age ; Allergies ; Allergy and Immunology ; Asthma ; atopic diathesis ; B-Lymphocytes - immunology ; B-Lymphocytes - metabolism ; bamboo hair ; Child ; Child, Preschool ; Comèl-Netherton syndrome ; Cytokines ; Cytokines - blood ; Cytotoxicity ; Deoxyribonucleic acid ; DNA ; Eczema ; Female ; Food ; Food allergies ; Humans ; ichthyosis ; immune deficiency ; Immune system ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Deficiency Syndromes - drug therapy ; Immunologic Deficiency Syndromes - genetics ; Immunologic Deficiency Syndromes - immunology ; Immunologic Factors - therapeutic use ; IVIG ; LEKTI ; Lymphocytes ; Male ; Mutation ; Natural Killer T-Cells - immunology ; Natural Killer T-Cells - metabolism ; NK-cell cytotoxicity ; Patients ; Pneumonia ; Proteinase Inhibitory Proteins, Secretory - biosynthesis ; Proteinase Inhibitory Proteins, Secretory - genetics ; Proteinase Inhibitory Proteins, Secretory - metabolism ; selective antibody deficiency ; Serine Peptidase Inhibitor Kazal-Type 5 ; SPINK5 ; Staphylococcal Skin Infections - drug therapy ; Staphylococcal Skin Infections - genetics ; Staphylococcal Skin Infections - immunology ; Staphylococcus aureus ; T-Lymphocytes, Regulatory - immunology ; T-Lymphocytes, Regulatory - metabolism</subject><ispartof>Journal of allergy and clinical immunology, 2009-09, Vol.124 (3), p.536-543</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2009 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright Elsevier Limited Sep 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33</citedby><cites>FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19683336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Renner, Ellen D., MD</creatorcontrib><creatorcontrib>Hartl, Dominik, MD</creatorcontrib><creatorcontrib>Rylaarsdam, Stacey, AAS</creatorcontrib><creatorcontrib>Young, Marguerite L., BS</creatorcontrib><creatorcontrib>Monaco-Shawver, Linda, BA</creatorcontrib><creatorcontrib>Kleiner, Gary, MD</creatorcontrib><creatorcontrib>Markert, M. Louise, MD</creatorcontrib><creatorcontrib>Stiehm, E. Richard, MD</creatorcontrib><creatorcontrib>Belohradsky, Bernd H., MD</creatorcontrib><creatorcontrib>Upton, Melissa P., MD</creatorcontrib><creatorcontrib>Torgerson, Troy R., MD, PhD</creatorcontrib><creatorcontrib>Orange, Jordan S., MD, PhD</creatorcontrib><creatorcontrib>Ochs, Hans D., MD</creatorcontrib><title>Comèl-Netherton syndrome defined as primary immunodeficiency</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background Mutations in serine protease inhibitor Kazal-type 5 ( SPINK5 ), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comèl-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic diathesis. Despite increased frequency of infections, the immunocompetence of patients with Comèl-Netherton syndrome has not been extensively investigated. Objective To define Comèl-Netherton syndrome as a primary immunodeficiency disorder and to explore the benefit of intravenous immunoglobulin replacement therapy. Methods We enrolled 9 patients with Comèl-Netherton syndrome, sequenced SPINK5, and analyzed LEKTI expression by immunohistochemistry. Immune function was assessed by measuring cognate immunity, serum cytokine levels, and natural killer cell cytotoxicity. Results All patients presented with recurrent skin infections caused predominantly by Staphylococcus aureus. All but 1 reported recurrent respiratory tract infections; 78% had sepsis and/or pneumonia; 67% had recurrent gastrointestinal disease and failure to thrive. Mutations in SPINK5 —including 6 novel mutations—were identified in 8 patients. LEKTI expression was decreased or absent in all patients. Immunologic evaluation revealed reduced memory B cells and defective responses to vaccination with Pneumovax and bacteriophage phiX174, characterized by impaired antibody amplification and class-switching. Immune dysregulation was suggested by a skewed T h 1 phenotype and elevated proinflammatory cytokine levels, whereas serum concentrations of the chemokine (C-C motif) ligand 5 and natural killer cell cytotoxicity were decreased. Treatment with intravenous immunoglobulin resulted in remarkable clinical improvement and temporarily increased natural killer cell cytotoxicity. Conclusion These data provide new insights into the immunopathology of Comèl-Netherton syndrome and demonstrate that this multisystem disorder, characterized by lack of LEKTI expression in epithelial cells, is complicated by cognate and innate immunodeficiency that responds favorably to intravenous immunoglobulin therapy.</description><subject>Age</subject><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Asthma</subject><subject>atopic diathesis</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - metabolism</subject><subject>bamboo hair</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Comèl-Netherton syndrome</subject><subject>Cytokines</subject><subject>Cytokines - blood</subject><subject>Cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Eczema</subject><subject>Female</subject><subject>Food</subject><subject>Food allergies</subject><subject>Humans</subject><subject>ichthyosis</subject><subject>immune deficiency</subject><subject>Immune system</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Deficiency Syndromes - drug therapy</subject><subject>Immunologic Deficiency Syndromes - genetics</subject><subject>Immunologic Deficiency Syndromes - immunology</subject><subject>Immunologic Factors - therapeutic use</subject><subject>IVIG</subject><subject>LEKTI</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Mutation</subject><subject>Natural Killer T-Cells - immunology</subject><subject>Natural Killer T-Cells - metabolism</subject><subject>NK-cell cytotoxicity</subject><subject>Patients</subject><subject>Pneumonia</subject><subject>Proteinase Inhibitory Proteins, Secretory - biosynthesis</subject><subject>Proteinase Inhibitory Proteins, Secretory - genetics</subject><subject>Proteinase Inhibitory Proteins, Secretory - metabolism</subject><subject>selective antibody deficiency</subject><subject>Serine Peptidase Inhibitor Kazal-Type 5</subject><subject>SPINK5</subject><subject>Staphylococcal Skin Infections - drug therapy</subject><subject>Staphylococcal Skin Infections - genetics</subject><subject>Staphylococcal Skin Infections - immunology</subject><subject>Staphylococcus aureus</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>T-Lymphocytes, Regulatory - metabolism</subject><issn>0091-6749</issn><issn>1097-6825</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQxi0EosvCC3BAkZC4JfhPYjsSVKpWlCJVcADOlmPPUofELnZSad-I9-DFcLqrlvZQTiN7fvNpZr5B6CXBFcGEv-2rXhtXUYzbCvMqh0doRXArSi5p8xit8g8puajbI_QspR7nN5PtU3REWi4ZY3yF3m_C-Of3UH6G6QLiFHyRdt7GMEJhYes82EKn4jK6Ucdd4cZx9mFJGAfe7J6jJ1s9JHhxiGv0_fTDt81Zef7l46fNyXlpOGNTSbcGWKMbTqg1ouFcGCNYa4XNfRBhqcQgOgy8bruO2aZjlNqu06buOMEdY2t0vNe9nLsRrAE_RT2oQ1sqaKfuZry7UD_ClWJcNkTUWeDNQSCGXzOkSY0uGRgG7SHMSXHBmWDN_0Ga9ys5oxl8fQ_swxx93oIiDa4laWRNMkX3lIkhpQjbm54JVouJqleLiWoxUWGuFovW6NW_096WHFzLwLs9AHnnVw6iStd-gHURzKRscA_rH98rN4PzzujhJ-wg3c6hElVYfV3OaLki3GIshSTsLymhw6I</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Renner, Ellen D., MD</creator><creator>Hartl, Dominik, MD</creator><creator>Rylaarsdam, Stacey, AAS</creator><creator>Young, Marguerite L., BS</creator><creator>Monaco-Shawver, Linda, BA</creator><creator>Kleiner, Gary, MD</creator><creator>Markert, M. Louise, MD</creator><creator>Stiehm, E. Richard, MD</creator><creator>Belohradsky, Bernd H., MD</creator><creator>Upton, Melissa P., MD</creator><creator>Torgerson, Troy R., MD, PhD</creator><creator>Orange, Jordan S., MD, PhD</creator><creator>Ochs, Hans D., MD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090901</creationdate><title>Comèl-Netherton syndrome defined as primary immunodeficiency</title><author>Renner, Ellen D., MD ; Hartl, Dominik, MD ; Rylaarsdam, Stacey, AAS ; Young, Marguerite L., BS ; Monaco-Shawver, Linda, BA ; Kleiner, Gary, MD ; Markert, M. Louise, MD ; Stiehm, E. Richard, MD ; Belohradsky, Bernd H., MD ; Upton, Melissa P., MD ; Torgerson, Troy R., MD, PhD ; Orange, Jordan S., MD, PhD ; Ochs, Hans D., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Age</topic><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Asthma</topic><topic>atopic diathesis</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - metabolism</topic><topic>bamboo hair</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Comèl-Netherton syndrome</topic><topic>Cytokines</topic><topic>Cytokines - blood</topic><topic>Cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Eczema</topic><topic>Female</topic><topic>Food</topic><topic>Food allergies</topic><topic>Humans</topic><topic>ichthyosis</topic><topic>immune deficiency</topic><topic>Immune system</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Deficiency Syndromes - drug therapy</topic><topic>Immunologic Deficiency Syndromes - genetics</topic><topic>Immunologic Deficiency Syndromes - immunology</topic><topic>Immunologic Factors - therapeutic use</topic><topic>IVIG</topic><topic>LEKTI</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Mutation</topic><topic>Natural Killer T-Cells - immunology</topic><topic>Natural Killer T-Cells - metabolism</topic><topic>NK-cell cytotoxicity</topic><topic>Patients</topic><topic>Pneumonia</topic><topic>Proteinase Inhibitory Proteins, Secretory - biosynthesis</topic><topic>Proteinase Inhibitory Proteins, Secretory - genetics</topic><topic>Proteinase Inhibitory Proteins, Secretory - metabolism</topic><topic>selective antibody deficiency</topic><topic>Serine Peptidase Inhibitor Kazal-Type 5</topic><topic>SPINK5</topic><topic>Staphylococcal Skin Infections - drug therapy</topic><topic>Staphylococcal Skin Infections - genetics</topic><topic>Staphylococcal Skin Infections - immunology</topic><topic>Staphylococcus aureus</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>T-Lymphocytes, Regulatory - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Renner, Ellen D., MD</creatorcontrib><creatorcontrib>Hartl, Dominik, MD</creatorcontrib><creatorcontrib>Rylaarsdam, Stacey, AAS</creatorcontrib><creatorcontrib>Young, Marguerite L., BS</creatorcontrib><creatorcontrib>Monaco-Shawver, Linda, BA</creatorcontrib><creatorcontrib>Kleiner, Gary, MD</creatorcontrib><creatorcontrib>Markert, M. Louise, MD</creatorcontrib><creatorcontrib>Stiehm, E. Richard, MD</creatorcontrib><creatorcontrib>Belohradsky, Bernd H., MD</creatorcontrib><creatorcontrib>Upton, Melissa P., MD</creatorcontrib><creatorcontrib>Torgerson, Troy R., MD, PhD</creatorcontrib><creatorcontrib>Orange, Jordan S., MD, PhD</creatorcontrib><creatorcontrib>Ochs, Hans D., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Renner, Ellen D., MD</au><au>Hartl, Dominik, MD</au><au>Rylaarsdam, Stacey, AAS</au><au>Young, Marguerite L., BS</au><au>Monaco-Shawver, Linda, BA</au><au>Kleiner, Gary, MD</au><au>Markert, M. Louise, MD</au><au>Stiehm, E. Richard, MD</au><au>Belohradsky, Bernd H., MD</au><au>Upton, Melissa P., MD</au><au>Torgerson, Troy R., MD, PhD</au><au>Orange, Jordan S., MD, PhD</au><au>Ochs, Hans D., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comèl-Netherton syndrome defined as primary immunodeficiency</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>124</volume><issue>3</issue><spage>536</spage><epage>543</epage><pages>536-543</pages><issn>0091-6749</issn><issn>1097-6825</issn><eissn>1097-6825</eissn><abstract>Background Mutations in serine protease inhibitor Kazal-type 5 ( SPINK5 ), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comèl-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic diathesis. Despite increased frequency of infections, the immunocompetence of patients with Comèl-Netherton syndrome has not been extensively investigated. Objective To define Comèl-Netherton syndrome as a primary immunodeficiency disorder and to explore the benefit of intravenous immunoglobulin replacement therapy. Methods We enrolled 9 patients with Comèl-Netherton syndrome, sequenced SPINK5, and analyzed LEKTI expression by immunohistochemistry. Immune function was assessed by measuring cognate immunity, serum cytokine levels, and natural killer cell cytotoxicity. Results All patients presented with recurrent skin infections caused predominantly by Staphylococcus aureus. All but 1 reported recurrent respiratory tract infections; 78% had sepsis and/or pneumonia; 67% had recurrent gastrointestinal disease and failure to thrive. Mutations in SPINK5 —including 6 novel mutations—were identified in 8 patients. LEKTI expression was decreased or absent in all patients. Immunologic evaluation revealed reduced memory B cells and defective responses to vaccination with Pneumovax and bacteriophage phiX174, characterized by impaired antibody amplification and class-switching. Immune dysregulation was suggested by a skewed T h 1 phenotype and elevated proinflammatory cytokine levels, whereas serum concentrations of the chemokine (C-C motif) ligand 5 and natural killer cell cytotoxicity were decreased. Treatment with intravenous immunoglobulin resulted in remarkable clinical improvement and temporarily increased natural killer cell cytotoxicity. Conclusion These data provide new insights into the immunopathology of Comèl-Netherton syndrome and demonstrate that this multisystem disorder, characterized by lack of LEKTI expression in epithelial cells, is complicated by cognate and innate immunodeficiency that responds favorably to intravenous immunoglobulin therapy.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>19683336</pmid><doi>10.1016/j.jaci.2009.06.009</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-6749 |
ispartof | Journal of allergy and clinical immunology, 2009-09, Vol.124 (3), p.536-543 |
issn | 0091-6749 1097-6825 1097-6825 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3685174 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Age Allergies Allergy and Immunology Asthma atopic diathesis B-Lymphocytes - immunology B-Lymphocytes - metabolism bamboo hair Child Child, Preschool Comèl-Netherton syndrome Cytokines Cytokines - blood Cytotoxicity Deoxyribonucleic acid DNA Eczema Female Food Food allergies Humans ichthyosis immune deficiency Immune system Immunoglobulins, Intravenous - therapeutic use Immunologic Deficiency Syndromes - drug therapy Immunologic Deficiency Syndromes - genetics Immunologic Deficiency Syndromes - immunology Immunologic Factors - therapeutic use IVIG LEKTI Lymphocytes Male Mutation Natural Killer T-Cells - immunology Natural Killer T-Cells - metabolism NK-cell cytotoxicity Patients Pneumonia Proteinase Inhibitory Proteins, Secretory - biosynthesis Proteinase Inhibitory Proteins, Secretory - genetics Proteinase Inhibitory Proteins, Secretory - metabolism selective antibody deficiency Serine Peptidase Inhibitor Kazal-Type 5 SPINK5 Staphylococcal Skin Infections - drug therapy Staphylococcal Skin Infections - genetics Staphylococcal Skin Infections - immunology Staphylococcus aureus T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - metabolism |
title | Comèl-Netherton syndrome defined as primary immunodeficiency |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A55%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Com%C3%A8l-Netherton%20syndrome%20defined%20as%20primary%20immunodeficiency&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Renner,%20Ellen%20D.,%20MD&rft.date=2009-09-01&rft.volume=124&rft.issue=3&rft.spage=536&rft.epage=543&rft.pages=536-543&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2009.06.009&rft_dat=%3Cproquest_pubme%3E21098632%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c633t-2fce35a5612dc75667cc739d7d96817d280e7b0e649bb3d5b322dbbac4b610b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504815841&rft_id=info:pmid/19683336&rfr_iscdi=true |